Early-stage treatment for T2DM would therefore require DR3 antagonization for increases in glucose tolerance and insulin sensitivity, followed by DR3 activation for the sustained maintenance of adipose trafficked ILC2s and increase in UCP1 expression and adipose browning. Here, TNFRSF25 is linked to type 2 diabetes mellitus.